UNIVERSITY OF NOVI SAD, FACULTY OF MEDICINE NOVI SAD

Their core work

The Faculty of Medicine at the University of Novi Sad is a Serbian academic medical institution that contributes clinical and translational research capacity to international consortia. Their H2020 work spans two distinct disease areas: metabolic liver disease (specifically NAFLD in obese patients, tested via natural Mastiha treatment) and genetic cardiomyopathy (familial disease driven by sarcomeric protein mutations). They bring clinical expertise — patient cohorts, clinical protocols, and medical data — to multi-country research collaborations, while also engaging with computational drug-trial methodologies as a specialist third party.

What they specialise in

How they've shifted over time

The faculty's earliest H2020 involvement (2016, MAST4HEALTH) centered on clinical nutrition and metabolic disease — specifically testing a natural compound in obese patients with liver disease. By 2018, their second engagement (SILICOFCM) shifted toward cardiac genetics and in silico drug-trial methodology, a markedly more computational and disease-genetics-oriented direction. With only two data points, this reads less as a deliberate pivot and more as opportunistic broadening — the faculty appears willing to contribute clinical expertise across different disease areas rather than deepening a single specialization.

The shift from nutritional hepatology toward computational cardiomyopathy research suggests this faculty is expanding its range of clinical domains, making them a potentially flexible partner for health consortia needing Balkan clinical site capacity across multiple disease areas.

How they like to work

This faculty has never led an H2020 project — all participation has been as a consortium partner or third party, consistently joining large international teams rather than building their own. The 32 unique partners across 11 countries from just two projects indicates they operate within well-networked, multi-site consortia rather than smaller bilateral collaborations. They function as a specialist clinical contributor: providing disease-area expertise, patient access, or local research infrastructure to projects coordinated by others.

Despite only two projects, the faculty has touched 32 distinct partner organizations across 11 countries — suggesting both projects were large, geographically distributed consortia. Their network is European in scope, though no dominant regional clustering is evident from the available data.

What sets them apart

As a faculty of medicine in Serbia — an EU-associated country — this institution offers value to consortia that need to include Western Balkans clinical sites or patient populations, which can fulfill geographic diversity requirements and broaden epidemiological study reach. Their dual exposure to metabolic disease and cardiac genetics gives them a foothold in two high-priority EU health research areas, even if neither is yet deeply developed. For consortium builders, they represent an accessible, lower-cost clinical partner with a track record in MSCA and RIA instruments.

Highlights from their portfolio

• MAST4HEALTH
  The only funded project (EUR 108,000 via MSCA-RISE), it tested a natural resin as a clinical intervention for NAFLD — an unusual intersection of traditional medicine and metabolic disease research that ran through 2020.
• SILICOFCM
  A landmark RIA project applying in silico (computational) drug trials to familial cardiomyopathy, representing the faculty's entry into computational medicine methodology — an emerging and fundable field.